What Happened?
Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ: HALO) jumped 18.1% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year financial guidance.
The biopharmaceutical company posted adjusted earnings of $2.28 per share on revenues of $481 million, easily beating consensus estimates of $1.82 per share and $404.3 million, respectively. Revenue grew 47.7% year on year, driven by royalties and milestone payments from its ENHANZE drug delivery platform.
Buoyed by the strong results, Halozyme increased its full-year revenue guidance to a midpoint of $1.87 billion and lifted its adjusted earnings per share forecast to a midpoint of $8.83.
The shares closed the day at $103.06, up 20.2% from the previous close.
Is now the time to buy Halozyme Therapeutics? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Halozyme Therapeutics’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. Moves this big are rare for Halozyme Therapeutics and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 2 months ago when the stock gained 5.2% on the news that an analyst reiterated a Buy rating on the stock, and a partner company, argenx, presented positive new data for a drug that utilizes Halozyme's technology. Benchmark maintained its Buy rating and $90 price target on Halozyme, with the firm noting the stock has potential for gains this year. The positive sentiment was reinforced by news from partner company argenx, which announced it would present new data for its drug, Efgartigimod. This development is significant for Halozyme because Efgartigimod uses its ENHANZE® drug delivery technology. This technology helps deliver biologic drugs through a subcutaneous injection, which is an injection under the skin. Positive results for a partner's product using ENHANZE can be viewed as a validation of Halozyme's core technology.
Halozyme Therapeutics is up 44.8% since the beginning of the year, and at $101.81 per share, it is trading close to its 52-week high of $103.12 from August 2026. Investors who bought $1,000 worth of Halozyme Therapeutics’s shares 5 years ago would now be looking at an investment worth $2,518.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
